Zhou GD, Li Q. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report. World J Clin Cases 2024; 12(11): 1967-1973 [PMID: 38660551 DOI: 10.12998/wjcc.v12.i11.1967]
Corresponding Author of This Article
Qin Li, MD, Lecturer, Surgeon, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, Shanghai, China. pekingli@163.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 16, 2024; 12(11): 1967-1973 Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1967
Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report
Guang-Di Zhou, Qin Li
Guang-Di Zhou, Affiliated to Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai 200092, China
Qin Li, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, Shanghai 200433, China
Author contributions: Li Q designed and performed the research; Both of Li Q and Zhou GD analyzed the data and wrote the paper.
Supported bythe “The Role and Molecular Mechanism of C20orf116 in Ovarian Cancer Cells”, Changhai Hospital Youth Start-up Fund.
Informed consent statement: The patient’s permission to publication is obtained.
Conflict-of-interest statement: All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.
CARE Checklist (2016) statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qin Li, MD, Lecturer, Surgeon, Department of Obstetrics and Gynecology, Shanghai Changhai Hospital, No. 168 Changhai Road, Yangpu District, Shanghai 200433, Shanghai, China. pekingli@163.com
Received: January 12, 2024 Peer-review started: January 12, 2024 First decision: January 31, 2024 Revised: February 8, 2024 Accepted: March 19, 2024 Article in press: March 19, 2024 Published online: April 16, 2024 Processing time: 89 Days and 17.3 Hours
Abstract
BACKGROUND
Ovarian cancer is the most common malignant tumor of the female reproductive system, and the survival rate of patients with relapsed and refractory ovarian cancer is very low.
CASE SUMMARY
Here, we report a case of high-grade serous papillary adenocarcinoma of the ovary that was successfully treated with immunotherapy. Radical surgery and adjuvant chemotherapy for the 56-year-old patient were successful; however, her tumor relapsed. Subsequent second-line chemotherapy, targeted agents, and other treatments were ineffective, as the tumor continued to recur and metastasize. Anti-programmed cell death-1 (PD-1) monotherapy (tislelizumab) completely alleviated the tumor, and the multiple metastatic tumors disappeared. To date, the patient has used anti-PD-1 for 32 months, experiencing no disease progression and maintaining good health without additional treatment.
CONCLUSION
This case suggests that anti-PD-1 immunotherapy may have long-term positive effects on outcomes in some refractory recurrent solid tumors. Further research is needed to identify patients most likely to respond to anti-PD-1 therapy.
Core Tip: When chemotherapy, poly adenosine diphosphate ribose polymerase inhibitors, and other treatments are ineffective for relapsed refractory ovarian cancer, anti-programmed death 1 immunotherapy may be the last resort.
